hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06304155 id: 202437 briefTitle: Application of FDG Combined With FAPI PET Dual Imaging in the Diagnosis and Staging of Oropharyngeal and Laryngeal Cancer overallStatus: RECRUITING date: 2024-01-01 date: 2026-01-01 date: 2026-01-01 date: 2024-03-12 date: 2024-03-15 name: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University class: OTHER briefSummary: According to statistics, in 2020, new head and neck malignancies in the world accounted for 4.9% (931931 cases) of malignant tumors in the whole body, and the new death cases were 467125, accounting for 4.7% of malignant tumors in the whole body. The high incidence rate and mortality brought great burden to the medical system. In addition, due to various types of head and neck cancer, hidden location, impact on function and quality of life, and low overall survival rate, this type of disease has seriously threatened human health and social development. The incidence of oropharyngeal cancer and laryngeal cancer is more subtle. Traditional examination methods include CT(computer tomography), MR(magnetic resonance), and laryngoscopy, but they cannot make accurate judgments on the systemic TNM(primary tumor, regional nodes, metastasis) staging of oropharyngeal cancer and laryngeal cancer. 18F-FDG(18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) PET/CT examination can better diagnose and stage compared to traditional examination methods. However, due to the interference of more inflammatory lesions or physiological uptake in the pharynx, the false positive rate of 18F-FDG PET/CT examination is significantly increased, 18F-FAPI(18F-fibroblast activation protein inhibitors) is a novel broad-spectrum tumor imaging agent that can be specifically uptake by fibroblasts in the tumor microenvironment, and has lower physiological uptake and acute inflammatory lesion uptake in the larynx. 18F-FAPI PET/CT examination can more accurately stage tumors throughout the body than 18F-FDG PET/CT examination. Combined with PET/MR local scanning, it will further improve the accuracy of T and N staging of local tumors. Therefore, It is of great significance for clinical diagnosis and treatment to effectively and reliably determine the systemic TNM staging of oropharyngeal and laryngeal cancer through non-invasive methods. conditions: Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 40 type: ESTIMATED name: Diagnostic efficacy,SUV measure: Diagnostic efficacy measure: SUV sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Nuclear Medicine, Daping Hospital of Army Medical University status: RECRUITING city: Chongqing state: Chongqing zip: 400010 country: China name: Xiao Chen, Ph.D role: CONTACT phone: 15922970174 email: xiaochen229@foxmail.com lat: 29.56278 lon: 106.55278 hasResults: False
nctId: NCT06304142 id: SGB-reflux briefTitle: Effect of Lidocaine Block on Gastroesophageal Reflux Disease overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-06 date: 2024-06 date: 2024-03-12 date: 2024-03-15 name: Muhammad class: OTHER briefSummary: The goal of this clinical trial is to explore Clinical Effect of Stellate Ganglion Block on Gastroesophageal Reflux Disease. The main question it aims to answer is:
• Can stellate ganglion block improve gastroesophageal reflux symptoms better on the basis of rehabilitation training? Participants will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Stellate Ganglion Block once a day additionally. The study lasts 10 days for each participant. Researchers will compare the Gastroesophageal Reflux Disease Questionnaire, Pressure pain threshold, Self-Evaluation Questionnaire for Gastroesophageal Reflux Disease, to see if the Stellate Ganglion Block can help improve the symptom. conditions: Gastroesophageal Reflux Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Rehabilitation therapy name: Injection name: Lidocaine hydrochloride measure: Gastroesophageal Reflux Disease Questionnaire measure: Pressure pain threshold measure: Modified Mayo Clinic Dysphagia-30 questionnaire sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06304129 id: 2023-A00709-36 briefTitle: Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers acronym: PLASM-ALZ overallStatus: NOT_YET_RECRUITING date: 2024-04-02 date: 2026-01-02 date: 2026-09-02 date: 2024-03-12 date: 2024-03-12 name: Central Hospital, Nancy, France class: OTHER name: Thérèse Jonveaux name: Laure Joly name: Lucie Hopes name: Maia Simon name: Franck Schreiner briefSummary: .The goal of this interventional study is to estimate the diagnostic performance of plasma biomarkers of interest (Aβ40 and Aβ42, P-Tau and NFL), enabling discrimination between patients with and without a pathophysiological AD process. The main questions it aims to answer are:
* to describe the final diagnosis and results obtained for plasma biomarkers, for patients with intermediate results according to the A/T/N classification (A-/T+ or A+/T-) Participants will be selected among patients undergoing lumbar puncture for the differential diagnosis of AD at Nancy University Hospital. conditions: Alzheimer Blood Biomarkers studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 189 type: ESTIMATED name: Blood ponction measure: Aβ40 and Aβ42, P-Tau, Tau and NFL measure: Sensitivity/specificity measure: Co-mobidity measure: Final diagnosis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHRU De Nancy city: Nancy state: Grand Est zip: 54500 country: France lat: 48.68439 lon: 6.18496 hasResults: False
nctId: NCT06304116 id: SGB-TBI briefTitle: Effect of Lidocaine Block in Traumatic Brain Injury overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-06 date: 2024-06 date: 2024-03-12 date: 2024-03-15 name: Muhammad class: OTHER briefSummary: The goal of this or clinical trial is to explore efficacy of stellate ganglion block on dysphagia and activities of daily living in Traumatic Brain Injury Patients. The main question it aims to answer are:
Traumatic Brain Injury Patients will be divided into the the control group and observation group evenly. All the patients were provided with routine therapy, while the patients in the observation group were given stellate ganglion block. The swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated. conditions: Traumatic Brain Injury studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Rehabilitation therapy name: Stellate ganglion block name: Lidocaine Hydrochloride measure: Penetration-Aspiration Scale measure: Modified Barthel Index measure: Swallowing duration measure: Functional Oral Intake Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06304103 id: AND017-MDS-206 briefTitle: A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome overallStatus: NOT_YET_RECRUITING date: 2024-12 date: 2026-12 date: 2027-05 date: 2024-03-12 date: 2024-03-15 name: Kind Pharmaceuticals LLC class: INDUSTRY briefSummary: This is a Phase 2, multicenter, randomized, open-lable study to evaluate the efficacy and safety of luspatercept (ACE-536) for the treatment of anemia due to lower risk Myelodysplastic syndromes (MDS)in patients subjects who are Red blood cell (RBC) non-transfusion dependent (NTD) and low transfusion burden (LTB). conditions: Myelodysplastic Syndromes studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 63 type: ESTIMATED name: AND017 measure: Percentage of HI-E/RBC-TI responding subjects measure: Mean level and change from baseline in untransfused Hb throughout the first 8 weeks of treatment measure: Mean level and change from baseline in untransfused Hb at each visit throughout the treatment period and measure: Percentage of visits in which untransfused Hb was maintained in this range after reaching two consecutive increases of ≥1.5 g/dL and ≥1.0 g/dL from baseline, respectively, throughout the treatment period measure: Mean time required after two consecutive increases in untransfused Hb ≥1.5 g/dL and ≥1.0 g/dL from baseline, respectively, throughout the treatment period measure: For changes in mean transfusion units throughout the treatment period compared to baseline (mean transfusion units 16 weeks prior to first dose) measure: For LTB cohorts, the average time required to reach first transfusion independence throughout the treatment period measure: Levels of reticulocyte count at each visit and change from baseline measure: Levels of hematocrit at each visit and change from baseline measure: Levels of mean corpuscular volume at each visit and change from baseline measure: Levels of mean corpuscular hemoglobin at each visit and change from baseline sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06304090 id: SGB-NT briefTitle: Efficacy of Lidocaine Block in Children With Cerebral Palsy and Dysphagia overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-12 date: 2024-12 date: 2024-03-12 date: 2024-03-15 name: Muhammad class: OTHER briefSummary: The goal of this clinical trial is to test the efficacy of stellate ganglion block in children with cerebral palsy and dysphagia. The main question it aims to answer are:
• Can stellate ganglion block improve the dysphagia of children with cerebral palsy? Participants were randomly divided into two groups, all provided with routine therapy. Based on this, the experimental group was given stellate ganglion block. The video fluoroscopic swallowing study was done to test the swallowing function before and after the study. conditions: Cerebral Palsy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: routine rehabilitation treatment name: Stellate ganglion block name: Lidocaine Hydrochloride measure: Penetration-Aspiration Scale measure: Functional Oral Intake Scale sex: ALL minimumAge: 4 Years maximumAge: 7 Years stdAges: CHILD hasResults: False
nctId: NCT06304064 id: CAP-1002-DMD-03 briefTitle: Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE) acronym: HOPE-OLE overallStatus: COMPLETED date: 2018-06-21 date: 2019-03-06 date: 2019-03-06 date: 2024-03-12 date: 2024-04-24 date: 2024-04-24 name: Capricor Inc. class: INDUSTRY briefSummary: This Phase 2, multi-center, open-label extension trial will provide CAP-1002 to participants who were randomized to the Usual Care treatment group of the HOPE-Duchenne study (NCT02485938) and completed 12 months of follow-up.
The trial will assess the safety and efficacy of two intravenous administrations of CAP-1002, each separated by three months. conditions: Duchenne Muscular Dystrophy studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 8 type: ACTUAL name: Allogeneic Cardiosphere-Derived Cells (CAP-1002) measure: Number of Participants Experiencing Acute Respiratory Decompensation measure: Number of Participants With Hypersensitivity Reactions measure: All-cause Mortality measure: Number of Treatment-emergent Adverse Events (TEAEs) Related to Investigational Product or Administration and Serious Adverse Events (SAEs) measure: Number of Participants With Immune Sensitization Syndrome sex: MALE minimumAge: 12 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University of Florida city: Gainesville state: Florida zip: 32610 country: United States lat: 29.65163 lon: -82.32483 facility: Cincinnati Children's Medical Center city: Cincinnati state: Ohio zip: 45229 country: United States lat: 39.12713 lon: -84.51435 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2018-02-12 uploadDate: 2024-03-29T13:28 filename: Prot_000.pdf size: 2102667 typeAbbrev: SAP hasProtocol: False hasSap: True hasIcf: False label: Statistical Analysis Plan date: 2019-03-26 uploadDate: 2024-03-29T13:25 filename: SAP_001.pdf size: 741616 hasResults: True
nctId: NCT06304051 id: Naochuxue-IOE briefTitle: Effect of Intermittent Oral Enteral Nutrition Tube in Tracheostomized Patients With Intracerebral Hemorrhage overallStatus: COMPLETED date: 2023-01-17 date: 2023-05-10 date: 2023-06-01 date: 2024-03-12 date: 2024-03-12 name: Muhammad class: OTHER briefSummary: This was a multicenter, prospective, randomized controlled clinical trail involved tracheostomized patients with Intracerebral Hemorrhage.
Participants will be divided into two groups randomly, with different nutritional support respectively. conditions: Intracerebral Hemorrhage studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 118 type: ACTUAL name: Intermittent Oro-esophageal Tube Feeding name: Nasogastric Tube Feeding measure: Number of cases of successful extubation measure: Body mass index measure: Serum albumin level measure: Hemoglobin level measure: Clinical Pulmonary Infection Score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hongkong central Hospital city: Hong Kong country: Hong Kong lat: 22.27832 lon: 114.17469 hasResults: False
nctId: NCT06304038 id: 2018 briefTitle: Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome overallStatus: COMPLETED date: 2017-10-16 date: 2018-04-29 date: 2019-11-14 date: 2024-03-12 date: 2024-03-12 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: Flu vaccination, as well as being effective to prevent seasonal influenza, decreases staff illness and absenteeism and reduces costs resulting from loss of productivity. Despite the effectiveness of flu vaccination, the seasonal coverage among healthcare workers is usually low. The aim of this retrospective observational study is to analyze the vaccination coverage rate among all employees (healthcare workers and administrative staff) of a large teaching hospital in Rome during the 2017-2018 influenza season, to perform a cost-consequence analysis of influenza vaccination (by evaluating the absenteeism due to illness in the epidemic period), and to assess the impact of vaccination in terms of both costs and sick days. conditions: Influenza Vaccine conditions: Cost-Benefit Analysis studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 5483 type: ACTUAL name: Flu Vaccine measure: Effectiveness of the quadrivalent vaccine measure: Economic impact of the quadrivalent vaccine measure: Expected economic savings for each one percentage point increase in vaccination coverage measure: Non-economic incentives for healthcare personnel who decide to vaccinate sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Universitario "A.Gemelli" IRCCS city: Rome zip: 00168 country: Italy lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06304025 id: GvHD 01 briefTitle: Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment acronym: GvHD overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-06 date: 2025-08 date: 2024-03-12 date: 2024-03-12 name: Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle class: OTHER name: Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud - IDCBIS briefSummary: Hematopoietic stem cell transplantation (HSCT) is the treatment of choice for malignant hemopathies, but highlights the limitations of long-term results due to the high toxicity of the procedure and the development of Graft versus Host Disease (GVHD). Conventional treatments for GVHD have limited success rates, and some patients may be refractory to ruxolitinib, a second-line treatment option. As a result, there is a need to explore alternative immuno-modulatory therapies, such as the use of Wharton's jelly mesenchymal stem cells (WJ-MSCs).
The research question aims to investigate the safety and potential benefits of sequentially infusing thawed or expanding allogeneic WJ-MSCs in the treatment of acute GVHD refractory to second-line treatment in patients from the Colombian population. This pilot clinical study is being conducted to address the unmet need for patients who develop GVHD resistant to ruxolitinib. conditions: Graft Versus Host Disease studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Experimental (pilot clinical study), randomized, blind, and parallel. primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 10 type: ESTIMATED name: Wharton's jelly mesenchymal stem cells (WJ-MSCs) measure: Incidence of treatment-emergent adverse events: safety and tolerability measure: Efficacy clinic profile: response of acute GVDH measure: Efficacy clinic profile : duration of response measure: Efficacy clinic profile: decrease in treatments measure: Efficacy biological profile: secretion pattern of soluble factors measure: Efficacy biological profile: cell populations measure: Efficacy biological profile: ocrrelation of the biological markers with the clinical response sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06304012 id: IOE-TBI lao briefTitle: Effect of Oral Enteral Nutrition on Severe Traumatic Brain Injury overallStatus: COMPLETED date: 2022-06-01 date: 2023-05-17 date: 2023-06-01 date: 2024-03-12 date: 2024-03-12 name: Muhammad class: OTHER briefSummary: This was a multicenter randomized controlled study of 98 severe Traumatic Brain Injury patients with tracheostomy. Patients enrolled were divided randomly into the observation group with Intermittent Oro-esophageal Tube Feeding (n=50) or the control group with Nasogastric tube feeding (n=48) for enteral nutrition support, respectively. Nutritional status, complications, decannulation of tracheostomy tubes and level of consciousness on day 1 and day 28 were recorded and compared. conditions: Traumatic Brain Injury studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 104 type: ACTUAL name: Nasogastric tube feeding name: Intermittent Oro-esophageal Tube Feeding name: Rehabilitation therapy measure: Concentration of hemoglobin measure: Concentration of albumin measure: Concentration of prealbumin measure: Nutritional status-body mass index measure: Complications-Pulmonary Infections measure: Complications-Gastroesophageal Reflux measure: Complications- Gastrointestinal Bleeding measure: Complications-Gastric Retention measure: Complications-Diarrhea measure: Complications-Constipation measure: Decannulation of tracheostomy tube-placement duration measure: Level of consciousness sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jiansheng Hos. city: Yilan country: Taiwan lat: 24.757 lon: 121.753 hasResults: False
nctId: NCT06303999 id: IOE-Small lao briefTitle: Effect of Oral Enteral Nutrition on Cerebral Small Vessel Disease overallStatus: COMPLETED date: 2023-01-01 date: 2023-06-02 date: 2023-06-15 date: 2024-03-12 date: 2024-03-12 name: Muhammad class: OTHER briefSummary: Nasogastric tube feeding (NGT) has been widely used in cerebral small vessel disease (CSVD) patients with dysphagia but has a significant risk of complications. Intermittent Oro-esophageal Tube Feeding (IOE) is an established enteral nutrition approach that can be used with comprehensive rehabilitation therapy. This study aims to explore the clinical effect of IOE vs. NGT on CSVD Patients with Dysphagia. Compared to NGT, IOE, as an enteral nutrition support mode, in CSVD Patients with Dysphagia who received comprehensive rehabilitation therapy, showed advantages in improvement in dysphagia, nutritional status, ADL, QOL, pneumonia, and adverse events, which should be considered as the preferred approach. conditions: Cerebral Small Vessel Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 60 type: ACTUAL name: Intermittent Oro-esophageal Tube name: Nasogastric tube measure: Functional Oral Intake Scale measure: Body mass index measure: Serum albumin measure: Hemoglobin measure: Pneumonia measure: Activities of daily living measure: World Health Organization Quality of Life Assessment Instrument Brief Version sex: ALL minimumAge: 40 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Huimin Hos. city: Pengfu country: Taiwan lat: 24.98333 lon: 121.41667 hasResults: False